Open-house drug discount agreements
Original notice title
Germany – Pharmaceutical products – Arzneimittelrabattverträge gem. § 130a Abs. 8 SGB V im Rahmen von Open-House-Verfahren
Opportunity Score
Why this score?
Opportunity
50 / 100
Complexity
15 / 100
Risk factors
No estimated contract value or framework maximum value disclosed; bidders cannot assess potential revenue.
Only the XML notice was analyzed; full procurement documents (agreement terms, self-declaration forms) have not been re...
Deep Portfolio Analysis
Uses:
- Description
- Industries & Services
- Capabilities
- Market & Experience
- Certifications
Overview
Moderate opportunityKey Facts
- Supplies contract
- 2 lots
- Duration until Jul 2027
- Supply of pharmaceutical products (Nilotinib and Diclofenac) under non-exclusive discount agreements.
- Framework agreements with IKK classic, running from August 1, 2025 to July 31, 2027.
Show full summary
Open House procedure by IKK classic for non-exclusive pharmaceutical discount agreements (Rabattverträge) under §130a SGB V for two active substances (Nilotinib and Diclofenac). Eligible pharmaceutical companies can join at any time from August 1, 2025, to July 31, 2027, subject to submission deadlines. No estimated values or award criteria provided. Submission via email or postal mail; electronic submission not allowed. Eligibility limited to pharmaceutical entrepreneurs per §4 Abs. 18 AMG.
Risks
No estimated contract value or framework maximum value disclosed; bidders cannot assess potential revenue.
Only the XML notice was analyzed; full procurement documents (agreement terms, self-declaration forms) have not been re...
Analysis may be incomplete
Only part of the procurement documentation was analyzed. Additional eligibility requirements, certificates, or submission documents may exist in the remaining tender documentation.
Key Requirements
Eligibility
- Only pharmaceutical entrepreneurs as defined in §4 Abs. 18 AMG are eligible (including consortia of such entrepreneurs).
Administrative
- Submission of signed contract, all required declarations and documents via email or postal mail; electronic submission not allowed.
- Documents must be submitted by the 5th of a month for contract start on the 1st of the following month (or later date if after the 5th).
Requirements may be incomplete.
Buyer
Lots (2)
LOT-0001
Nilotinib
Nilotinib, allowed only for administration dispersed in applesauce, ATC Code L01AE03. Framework agreement for supply of pharmaceuticals. Performance in DEU, region DED21.
Location
Duration
Category
Deadline
Award details
Nilotinib
nur mit zulässiger Verabreichung dispergiert in Apfelmus
ATC-Code: L01AE03
Value note
Show original TED data
Original lot title
Nilotinib; nur mit zulässiger Verabreichung dispergiert in Apfelmus; ATC-Code: L01AE03
Original TED description
Nilotinib; nur mit zulässiger Verabreichung dispergiert in Apfelmus; ATC-Code: L01AE03
LOT-0002
Diclofenac
Diclofenac retard capsules and tablets, strengths 75 mg (pack sizes 30, N2, N3) and 150 mg (pack sizes 10, N1), ATC Code M01AB05. Framework agreement for supply of pharmaceuticals. Performance in DEU, region DED21.
Location
Duration
Category
Deadline
Award details
Diclofenac
Retardkapseln, Retardtabletten
ATC-Code: M01AB05
Wirkstärke 75 mg mit Packungsgrößen: 30, N2, N3
Wirkstärke 150 mg mit Packungsgrößen 10, N1
Value note
Show original TED data
Original lot title
Diclofenac; Retardkapseln, Retardtabletten; ATC-Code: M01AB05; Wirkstärke 75 mg mit Packungsgrößen: 30, N2, N3; Wirkstärke 150 mg mit Packungsgrößen 10, N1
Original TED description
Diclofenac; Retardkapseln, Retardtabletten; ATC-Code: M01AB05; Wirkstärke 75 mg mit Packungsgrößen: 30, N2, N3; Wirkstärke 150 mg mit Packungsgrößen 10, N1
Procurement Details
- Publication date
- 19 Jun 2025
- Languages
- German
Reference metadata
- Legal basis
- 32014L0024
Reference IDs
- Tender ID
- 400529-2025
Documents (1)
Similar tenders
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)
Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР
Belgium – Pharmaceutical products – Antimycotica
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)
Denmark – Pharmaceutical products – Amgros 2027 1.1170.a
Opportunity Score
Why this score?
Opportunity
50 / 100
Complexity
15 / 100
Risk factors
No estimated contract value or framework maximum value disclosed; bidders cannot assess potential revenue.
Only the XML notice was analyzed; full procurement documents (agreement terms, self-declaration forms) have not been re...
Deep Portfolio Analysis
Uses:
- Description
- Industries & Services
- Capabilities
- Market & Experience
- Certifications